Payment overview · 2025
General Payments
$886.55
28 reported records · 14 companies
Healthcare provider profile · identity verified
Luis A Reynoso, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HARLINGEN, TX · NPI 1063402741
Verified facts
What the public records show
CMS Open Payments records show Luis A Reynoso, MD received $886.55 in general payments during 2025 across 28 reported records.
Lilly USA, LLC accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 493 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $280.57 | 31.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $205.24 | 23.1% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $64.62 | 7.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.02 | 5.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.40 | 5.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.72 | 4.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.86 | 4.4% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.64 | 3.9% | 2 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $32.31 | 3.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.70 | 3.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.62 | 2.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.63 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.33 | 1.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.89 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $844.05 | 27 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $258.22 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $205.24 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $81.95 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $81.95 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $64.62 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.34 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.02 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.40 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.72 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.86 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $34.64 | 2 | 2025 |
Source payment records
|
|||||
| BD Onclarity Normalized: bd onclarity |
Device | Becton, Dickinson and Company | $32.31 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.70 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 76 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 134 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 239 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 493 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 25 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
239 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
135 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
493 | 90 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
281 | 62 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 1035 | 312 |
| Metformin Hcl | Metformin Hcl | 801 | 222 |
| Atorvastatin Calcium | Atorvastatin Calcium | 718 | 198 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 713 | 233 |
| Levothyroxine Sodium | Levothyroxine Sodium | 616 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 596 | 176 |
| Metoprolol Succinate | Metoprolol Succinate | 574 | 157 |
| Pantoprazole Sodium | Pantoprazole Sodium | 508 | 149 |
| Ozempic | Semaglutide | 493 | 90 |
| Pravastatin Sodium | Pravastatin Sodium | 437 | 127 |
| Simvastatin | Simvastatin | 419 | 118 |
| Gabapentin | Gabapentin | 416 | 107 |
| Baclofen | Baclofen | 395 | 151 |
| Tamsulosin Hcl | Tamsulosin Hcl | 383 | 109 |
| Omeprazole | Omeprazole | 347 | 105 |
| Losartan Potassium | Losartan Potassium | 340 | 100 |
| Clopidogrel | Clopidogrel Bisulfate | 331 | 89 |
| Furosemide | Furosemide | 330 | 97 |
| Memantine Hcl | Memantine Hcl | 293 | 50 |
| Famotidine | Famotidine | 290 | 90 |
| Eliquis | Apixaban | 281 | 62 |
| Naproxen | Naproxen | 264 | 149 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 251 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 239 | 67 |
| Mounjaro | Tirzepatide | 239 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 237 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 226 | 63 |
| Donepezil Hcl | Donepezil Hcl | 225 | 43 |
| Trazodone Hcl | Trazodone Hcl | 225 | 62 |
| Glipizide | Glipizide | 212 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 113 |
| Alendronate Sodium | Alendronate Sodium | 204 | 52 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 201 | 177 |
| Finasteride | Finasteride | 181 | 50 |
| Montelukast Sodium | Montelukast Sodium | 180 | 50 |
| Valsartan | Valsartan | 168 | 55 |
| Carvedilol | Carvedilol | 166 | 44 |
| Prednisone | Prednisone | 165 | 61 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 161 | 99 |
| Xarelto | Rivaroxaban | 150 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 144 | 36 |
| Sertraline Hcl | Sertraline Hcl | 142 | 34 |
| Trulicity | Dulaglutide | 135 | 27 |
| Jardiance | Empagliflozin | 134 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 131 | 47 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 130 | 109 |
| Clonidine | Clonidine | 127 | 26 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 125 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 124 | 37 |
| Buspirone Hcl | Buspirone Hcl | 121 | 30 |
| Fenofibrate | Fenofibrate Nanocrystallized | 119 | 39 |
| Tramadol Hcl | Tramadol Hcl | 119 | 48 |
| Cephalexin | Cephalexin | 109 | 94 |
| Mirtazapine | Mirtazapine | 98 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 96 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 16 |
| Telmisartan | Telmisartan | 91 | 23 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 85 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 85 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 82 | 12 |
| Celecoxib | Celecoxib | 81 | 28 |
| Meclizine Hcl | Meclizine Hcl | 80 | 40 |
| Levetiracetam | Levetiracetam | 79 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 78 | 51 |
| Tresiba Flextouch U-200 | Insulin Degludec | 78 | 21 |
| Glipizide Er | Glipizide | 77 | 21 |
| Ezetimibe | Ezetimibe | 76 | 22 |
| Farxiga | Dapagliflozin Propanediol | 76 | 25 |
| Pregabalin | Pregabalin | 76 | 20 |
| Allopurinol | Allopurinol | 75 | 25 |
| Potassium Chloride | Potassium Chloride | 74 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 24 |
| Cefuroxime | Cefuroxime Axetil | 67 | 63 |
| Tresiba Flextouch U-100 | Insulin Degludec | 63 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 28 |
| Linzess | Linaclotide | 59 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 29 |
| Lactulose | Lactulose | 55 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 20 |
| Januvia | Sitagliptin Phosphate | 54 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | 17 |
| Metformin Hcl Er | Metformin Hcl | 53 | 21 |
| Sucralfate | Sucralfate | 53 | 12 |
| Nifedipine Er | Nifedipine | 52 | 14 |
| Methocarbamol | Methocarbamol | 51 | 36 |
| Fluconazole | Fluconazole | 50 | 32 |
| Venlafaxine Hcl | Venlafaxine Hcl | 49 | 17 |
| Ibuprofen | Ibuprofen | 48 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 48 | suppressed |
| Meloxicam | Meloxicam | 47 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 46 | 18 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 43 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 16 |
| Atenolol | Atenolol | 42 | 11 |
| Rybelsus | Semaglutide | 42 | suppressed |
| Digoxin | Digoxin | 41 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 40 | 15 |
| Vascepa | Icosapent Ethyl | 40 | 11 |
| Entresto | Sacubitril/Valsartan | 39 | 13 |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 37 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 32 |
| Azithromycin | Azithromycin | 33 | 32 |
| Diltiazem Hcl | Diltiazem Hcl | 33 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | 19 |
| Latanoprost | Latanoprost | 33 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 31 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 13 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Cyclosporine | Cyclosporine | 31 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 31 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 29 | suppressed |
| Cilostazol | Cilostazol | 28 | suppressed |
| Insulin Lispro | Insulin Lispro | 28 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 28 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 19 |
| Olanzapine | Olanzapine | 27 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 11 |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 21 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | 12 |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | 17 |
| Fentanyl | Fentanyl | 23 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | 11 |
| Risperidone | Risperidone | 20 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 18 |
| Rivastigmine | Rivastigmine Tartrate | 19 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Phenytoin | Phenytoin | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Nystatin | Nystatin | 16 | 12 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 14 | 12 |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Incontrol Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Nystop | Nystatin | 13 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $886.55 · 28 records | Lilly USA, LLC | AFREZZA, AIRSUPRA, BD Onclarity, BREZTRI, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE, INSPIRE, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, REPATHA, Rybelsus, VRAYLAR, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error